Akeso’s Ivonescimab Outshines Pembrolizumab on Overall Survival in Phase 3 HARMONi-2 Trial
China’s Akeso has reported another major clinical milestone for ivonescimab (AK112), its first-in-class PD-1/VEGF bispecific antibody, announcing that the drug demonstrated a statistically significant and clinically meaningful overall survival (OS)…
ALLYRNA Raises Over RMB 100 Million to Advance RNA Epigenetics-Based Cancer Drug Pipeline
Shanghai-based ALLYRNA has raised more than RMB 100 million in Seed+ financing to advance a new generation of small-molecule cancer therapies derived from RNA epigenetics, including potential radiotherapy and immunotherapy sensitizers for…
CStone Pharmaceuticals
Building Globally Competitive Innovative Medicines
TYK Medicines Wins China Approval for Asandeutertinib in EGFR-Mutant NSCLC With Brain Metastases
China’s NMPA has granted conditional approval to asandeutertinib (TY-9591), TYK Medicines’ brain-penetrant, deuterated EGFR inhibitor, for the first-line treatment of patients with EGFR-mutated non-small cell lung cancer with central nervous…
CSPC’s EGFR ADC SYS6010 Beats Chemotherapy in Phase 3 NSCLC Trial, Setting Stage for Potential Regulatory Filing
CSPC Pharmaceutical Group’s experimental EGFR-targeting antibody-drug conjugate SYS6010 has met the primary endpoint in the pivotal Phase III SYNSTAR-01 trial, significantly improving progression-free survival over platinum-based chemotherapy in…
Kelun-Biotech’s TROP2 ADC Sac-TMT Shows Durable Activity Across Genomically Altered NSCLC in a Phase 2 Study
Sichuan Kelun-Biotech has reported new Phase 2 data for its TROP2-directed antibody-drug conjugate sacituzumab tirumotecan (sac-TMT; SKB264/MK-2870) in heavily pretreated non-small cell lung cancer (NSCLC), showing durable antitumor activity across…
Biokin’s Iza-bren hits Phase 3 PFS endpoint in EGFR-Mutant NSCLC, marking 4th positive Phase 3 trial
Sichuan Biokin Pharmaceutical’s izalontamab brengitecan (iza-bren, BL-B01D1) has achieved another major clinical milestone, with the company reporting that its Phase 3 BL-B01D1-301 study in previously treated EGFR-mutant non-small cell lung cancer…
HUTCHMED’s Savolitinib-Tagrisso Combo Delivers Positive Phase 3 Results in MET-Driven EGFR-Mutated NSCLC
HUTCHMED has announced positive topline results from the global Phase 3 SAFFRON trial, showing that the combination of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) delivered statistically significant and clinically meaningful improvements in both…
GenFleet launches world’s first Phase 3 study of an oral KRAS G12D inhibitor for the treatment of NSCLC
GenFleet Therapeutics today held a national investigator conference for its Phase III registrational clinical trial of GFH375 (an oral KRAS G12D inhibitor) as monotherapy for non-small cell lung cancer (NSCLC) (“Kylin-Flight 01”). “Kylin-Flight 01” is a…